.: OKULISTYKA :.

Wydanie 1/2016
str. 58 - 65

Leki biologiczne w okulistyce – obecny stan wiedzy

Biological Agents in Ophthalmology – Current Knowledge

Małgorzata Figurska, Izabela Jamiołkowska, Marek Rękas

Klinika Okulistyki CSK MON
Wojskowy Instytut Medyczny w Warszawie
Kierownik: prof. dr hab. n. med. Marek Rękas

Summary: Biological agents have shifted the treatment paradigm for many ophthalmic diseases, especially non-infectious uveitis in the course of birdshot retinopathy, sarcoidosis, spondyloarthropathy, juvenile idiopathic arthritis, Behçet’s disease, and other rare disease entities, such as Vogt-Koyanaga-Harada. In anterior segment autoimmune diseases management, biological agents can be used for example in peripheral ulcerative keratitis. Although they are still used mainly in cases of ineffectiveness or adverse effects of standard immunosuppressive therapy, they are gaining recognition and indications for their use widen.
The most commonly studied systemic biologics are monoclonal antibodies against tumor necrosis factor alpha: infliximab, adalimumab and etanercept. The article also refers to studies with less frequently used in ophthalmology agents such as rituximab, dacilizumab, tocilizumab, abatacept, and secukinumab. Most of biological agents are administered systemically. There are reports of their topical application in the form of intravitreal injections or eye drops. What is new is the use of biological agents in ophthalmic surgery. Treatment with biological agents requires a careful monitoring of safety profile and is linked with an increased risk of developing cancer, opportunistic infections, demyelinating diseases and other autoimmune diseases.

Słowa kluczowe: leki biologiczne, infliksimab, adalimumab, etanercept, rytuksymab, dacilizumab, tocilizumab, secukinumab, abatacept, zapalenie nieinfekcyjne błony naczyniowej.

Keywords: biological agents, infliximab, adalimumab, etanercept, rituximab, dacilizumab, tocilizumab, secukinumab, abatacep, non-infectious uveitis.

powrót